Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes

Recruiting now

Conditions studied: Leukemia

In brief

The aim of this study is to look for predisposing mutations in patients and relatives affected by AML and MDS with familial history of myeloid or, less frequently, lymphoid malignancies. Taking advantage of a next generation sequencing (NGS) platform, screening for known and unknown mutations potentially associated with the disease will be done. The screening will be performed on affected and unaffected family members, in order to outline new pedigrees that either validate previous findings or constitute novel discoveries.

Key facts

Study ID

NCT03058588

Run by

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

People needed

20

Starts

2017-02-09

Expected to finish

2026-12-31

Last updated by the study team

2026-04-30

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any patient with acute myeloid leukemia (AML) or Myelodisplastic Syndrome (MDS) with:
• a first- or second-degree relative with Acute leukemia or MDS or other myeloid malignancies
• a first- or second-degree relative with Lymphoproliferative neoplasms
• or with clinical features that resemble one of the familial MDS/AML predisposition syndromes:
• History of thrombocytopenia and/or a clinical bleeding propensity (as in RUNX1, ANKRD26 or ETV6 germline mutations)
• Abnormal nails or skin pigmentation, oral leukoplakia, idiopathic pulmonary fibrosis, unexplained liver disease (as in TERT and TERC germline mutations)
• Lymphedema, atypical infections, immune deficiencies (as in GATA2 germline mutations)

You may not qualify if…

• any diagnosis other than acute myeloid leukemia (AML) or Myelodisplastic Syndrome (MDS);
• acute myeloid leukemia (AML) or Myelodisplastic Syndrome (MDS) without a first- or second-degree relative with Acute leukemia or MDS or other myeloid malignancies or without a first- or second-degree relative with Lymphoproliferative neoplasms or with clinical features that resemble one of the familial MDS/AML predisposition syndromes;
• unability to sign the informed consent

Where it is running

• Chair of Hematology and Bone marrow Transplant Unit — Brescia, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.